Ablexis Status
The company was acquired by Deerfield Management through an LBO on June 21, 2018 for an undisclosed sum.
Provider of a drug discovery platform designed to broaden enablement of the efficient discovery of the next generation of breakthrough antibody drugs. The company's AlivaMab Mouse platform is an innovative, next-generation transgenic mouse platform, enabling biotechnology and pharmaceutical companies to efficiently discover and develop the next generation of human therapeutic antibodies to treat human diseases.
Generating Revenue
Privately Held (backing)
Venture Capital-Backed
The company was acquired by Deerfield Management through an LBO on June 21, 2018 for an undisclosed sum.
Most visits will take between 1.5 and 2 hours. The agenda for a specific visit depends on your group, its interests and objectives as well as on the host company. A visit may include a company or industry specific presentation, a discussion around a specific product or service, partnership opportunities, a demo, a meeting of the premises, etc.
Add a review